Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is defined as the presence of ≥5% of hepatic steatosis (HS) in the absence of other liver disorders, such as chronic viral or autoimmune hepatitis, steatosis induced by drugs, significant alcohol consumption, hemochromatosis, or Wilson’s disease. There is limited literature describing national prevalence and epidemiological characteristics of NAFLD in […]

Background: As of April 2020, the Center for Disease Control and Prevention recommends one-time Hepatitis C testing for all adults age 18 and over and all pregnant women during every pregnancy. Previous research shows that Emergency Departments (ED) are effective settings for screening and diagnosing individuals for Hepatitis C Virus (HCV). The purpose of this […]

Case Presentation: A 77-year-old female was admitted with a 3-week history of pruritus and a 1-week history of jaundice and fatigue. Patient had not used any new medications, except for recently prescribed ACE inhibitors. There was no history of alcohol abuse or liver disease and no recent sick contacts. Other medical conditions are type 2 […]

Case Presentation: A 19-year-old female presented with 1 month of worsening abdominal pain, 3 weeks of fevers / chills, 1 week of nausea/vomiting, and 4 days of rash. Her abdominal pain was intermittent, stabbing, diffuse, and worsening in severity. She also had daily chills and fevers (maximum temperature of 38.9 °C). Her emesis was non-bilious […]

Case Presentation: Immune checkpoint inhibitors have evolved into the conventional therapy regimen for many cancer types. The major categories of immune checkpoint inhibitors include monoclonal antibodies against cytotoxic T lymphocyte antigen (CTLA-4), programmed cell death protein-1 (PD-1) and programmed cell death ligand molecules (PD-L1). Pembrolizumab has been implicated in causing hepatitis Discussion: An 89-year-old Caucasian […]

Background: One in three heavy drinkers experience acute alcohol-associated hepatitis (AAH). AAH is defined as acute liver injury with elevated bilirubin and AST/ALT ratio >1.5 in the setting of heavy alcohol use. AAH has a high mortality rate and is associated with development of chronic liver disease; thus, it is crucial to correctly identify patients […]